Core Points - Enovis Corporation announced the appointment of Damien McDonald as CEO, effective May 12, 2025, succeeding Matt Trerotola who will retire [1][3] - The company expects first quarter revenues to be between $555 million and $563 million, with adjusted EBITDA projected to be between $97 million and $100 million [1][6] Leadership Transition - Sharon Wienbar, Lead Independent Director, expressed enthusiasm for McDonald's appointment, highlighting his strong track record in the medical technology sector [2] - McDonald has over 35 years of experience in the medical device industry, previously serving as CEO of LivaNova, where he improved growth, profitability, and shareholder value [2][3] - Following Trerotola's retirement, Wienbar will assume the role of independent Chair of the Board [3] Company Overview - Enovis Corporation is focused on developing clinically differentiated medical technology solutions aimed at improving patient outcomes [4] - The company emphasizes a culture of continuous improvement and innovation, with a diverse range of products and services in orthopedics and beyond [4]

Core Insights - Enovis is showcasing its expanding portfolio of foot and ankle solutions at the ACFAS Annual Scientific Conference, emphasizing its commitment to education and innovative partnerships in the field [2][3]. Product Highlights - The company will feature the Tarsoplasty Percutaneous Lapidus Correction System, which offers a minimally invasive option for Lapidus bunionectomy, enhancing the patient's perioperative experience [3]. - Enovis will present new research on the Arsenal Foot™ Plating System, focusing on how screw angulation and plate design affect surgical outcomes [3]. Events and Engagements - Enovis is hosting two key events during the conference: "Phoenix Rising: Foot & Ankle Edition" on March 28 and a Flatfoot/MIS Techniques Workshop on March 26 [4]. - Attendees are encouraged to visit booth 1820 for hands-on engagement with Enovis products and to follow the company's social media for live updates [5]. Company Overview - Enovis Corporation is a medical technology growth company focused on developing clinically differentiated solutions that improve patient outcomes and transform workflows [6].

Core Insights - The article does not provide specific insights or analysis regarding any companies or industries, focusing instead on disclaimers and disclosures related to the author's position and affiliations [1][2]. Summary by Sections - No relevant company or industry information is presented in the content provided, as it primarily consists of disclaimers and disclosures without any analytical content [1][2].

Enovis Corporation (NYSE:ENOV) Q4 2024 Results Conference Call February 26, 2025 8:30 AM ET Company Participants Kyle Rose - Vice President of Investor Relations Matt Trerotola - CEO & Chairman Ben Berry - Senior VP & CFO Conference Call Participants Vic Chopra - Wells Fargo Vijay Kumar - Evercore ISI Robbie Marcus - JPMorgan Jeff Johnson - Baird Brandon Vazquez - William Blair Danielle Antalffy - UBS Mike Matson - Needham & Company Caitlin Cronin - Canaccord Jason Wittes - ROTH Operator Good day, and welco ...

Financial Data and Key Metrics Changes - In Q4 2024, Enovis reported sales of $561 million, representing a 23% increase year-over-year and a 7% increase on a constant currency basis [18][22] - Adjusted gross margin for Q4 was 60.1%, up 150 basis points year-over-year, driven by favorable segment mix including the addition of Lima [20] - Adjusted EBITDA grew 38% in Q4, delivering a margin of 20.1%, an increase of 210 basis points compared to the same quarter last year [21][25] - Adjusted earnings per share reached $0.98, a 24% increase from the prior year [22] Business Line Data and Key Metrics Changes - The Recon segment experienced 59% reported global revenue growth, with a 10% increase on a comparable basis in Q4 [10][19] - U.S. Recon grew 7%, with 10% growth in U.S. Extremities and 8% in Hip Knees [10] - The P&R segment saw stable growth of 3%, with EBITDA margins expanding by 130 basis points year-over-year [15][16] Market Data and Key Metrics Changes - International revenue in Recon grew by 13%, supported by successful integration plans and new product launches [11] - The company anticipates high single-digit growth in Recon for 2025, with stable low single-digit growth in P&R [26] Company Strategy and Development Direction - Enovis aims for continued growth through new product launches and cross-selling opportunities, particularly in the Recon segment [12][34] - The Lima acquisition has been pivotal in enhancing the Recon business, with successful integration and exceeding revenue and profit goals [13][14] - The company plans to focus on small bolt-on acquisitions in 2025 while continuing to integrate Lima and improve operational efficiencies [44][46] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term strategic goals and operational performance, despite a non-cash goodwill impairment of $645 million due to a decrease in share price [23][24] - The company expects 2025 to be another year of strong execution, with revenue guidance of $2.19 billion to $2.22 billion and adjusted EBITDA in the range of $405 million to $415 million [26][28] - Management highlighted the importance of navigating tariff impacts and maintaining supply chain resilience [31][33] Other Important Information - The company is preparing for a leadership transition as the CEO plans to retire later in the year, with an active search for a successor [36][39] - The company expects to achieve positive free cash flow in 2025 while continuing to invest in growth and integration efforts [72][74] Q&A Session Summary Question: M&A strategy post-Lima - Management indicated that 2025 will focus on small bolt-on acquisitions while completing the Lima integration and starting to deleverage the company [44][46] Question: Pathway to double-digit growth in Recon - Management believes there are multiple paths to achieve double-digit growth in Recon, but has set a strategic goal of high single digits for 2025 [49][51] Question: Q1 phasing and contribution - The company expects 2 to 3 extra selling days in Q1, contributing to a strong start, with momentum building in the business [54][56] Question: Margin guidance for 2025 - Management expects 60 to 70 basis points of margin improvement in 2025, driven by core operating leverage and synergies from the Lima acquisition [58][60] Question: U.S. vs. OUS market dynamics - Management noted strong demand outside the U.S. and a gradual improvement in the U.S. market, with expectations for continued share gains across all anatomies [64][70] Question: Free cash flow and debt outlook - The company anticipates positive free cash flow in 2025, with a goal to reduce leverage from 3.5x to the low 3s by year-end [72][74] Question: Pricing assumptions for 2025 - Management expects a return to some downward price pressure in the Recon segment, while P&R is anticipated to remain flat [76][80] Question: Lima integration status - The integration is largely complete, with key channel integrations and product roadmaps finalized, now focusing on cross-selling and operational improvements [88][92] Question: Tariff mitigation strategies - The company is implementing multiple sourcing strategies and inventory management to mitigate tariff impacts, with a focus on long-term health [98][100]

Group 1 - Enovis reported quarterly earnings of $0.98 per share, exceeding the Zacks Consensus Estimate of $0.92 per share, and up from $0.79 per share a year ago, representing an earnings surprise of 6.52% [1] - The company posted revenues of $560.98 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 0.84%, and an increase from $455.02 million year-over-year [2] - Enovis has surpassed consensus EPS estimates three times over the last four quarters, indicating a positive trend in earnings performance [2] Group 2 - The stock has underperformed the market, losing about 4.1% since the beginning of the year compared to the S&P 500's gain of 1.3% [3] - The current consensus EPS estimate for the upcoming quarter is $0.68 on revenues of $552.17 million, and for the current fiscal year, it is $3.19 on revenues of $2.23 billion [7] - The Zacks Industry Rank places Medical Info Systems in the bottom 49% of over 250 Zacks industries, suggesting potential challenges for stock performance [8]

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______to_______ Commission file number 001-34045 _________________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________ Form 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ENOVIS CORPORATION (Exact name of registrant as specified in its charter) S ...

Enovis Announces Fourth Quarter and Full Year 2024 Results WILMINGTON, DE, February 26, 2025 (GLOBE NEWSWIRE)—Enovis™ Corporation (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the fourth quarter and full year ended December 31, 2024. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET. Fourth Quarter and Fiscal Year 2024 Financial Results Enovis' fourth-quarter net sales of $561 mill ...

Core Insights - Enovis Corporation reported a strong financial performance for the fourth quarter and full year of 2024, with net sales reaching $561 million in Q4, representing a 23% increase year-over-year [2][5] - The company experienced significant growth in its Global Reconstructive segment, particularly due to the acquisition of Lima, with reported sales growth of 59% in Q4 [2][9] - Despite the sales growth, Enovis reported a net loss from continuing operations of $704 million in Q4, primarily due to a non-cash goodwill impairment charge of $645 million [3][4] Financial Performance - Fourth-quarter net sales of $561 million grew 23% on a reported basis and 6% on a Comparable Sales basis compared to Q4 2023 [2] - Full-year 2024 net sales totaled $2.1 billion, also reflecting a 23% increase on a reported basis [5] - Adjusted EBITDA for Q4 was $113 million, or 20% of sales, marking a 210 basis points increase from the prior year [3] Segment Performance - The Reconstructive segment saw a 59% increase in net sales on a reported basis in Q4, with a 10% growth in Comparable Sales [2][9] - The Prevention & Recovery segment experienced a modest growth of 2% on a reported basis in Q4 [2] Future Outlook - For 2025, Enovis expects revenue to be in the range of $2.19 to $2.22 billion, indicating an organic growth of 6-6.5% [6] - Adjusted EBITDA for 2025 is forecasted to be between $405 million and $415 million, representing a year-over-year expansion of 60-70 basis points [6] Leadership Transition - CEO Matt Trerotola announced his intention to retire, with the transition to a new CEO to be addressed during the financial results conference call [10]

Core Viewpoint - Enovis Corporation announced the retirement of CEO Matt Trerotola, effective upon the appointment of his successor, as part of the company's succession planning process [1][2][3] Group 1: Leadership Transition - The Board of Directors is actively working with an executive search firm to find a growth-oriented MedTech leader to succeed Trerotola [1] - Trerotola will continue to serve as an employee and Executive Advisor for one year after the new CEO is appointed to ensure a smooth transition [2] - Trerotola expressed pride in the company's accomplishments and emphasized that now is the right time for leadership transition due to the company's strong position for continued growth [3] Group 2: Company Overview - Enovis Corporation is a leader in medical technology innovation, focusing on developing clinically differentiated solutions that improve patient outcomes [4] - The company is dedicated to continuous improvement and innovation, with a wide range of products and services aimed at enhancing active lifestyles in orthopedics and beyond [4]